UNC2025|UNC-2025|Mer/Flt3 dual inhibitor

Cas No.:	1429881-91-3
Chemical Name:	(1r,4r)-4-(2-(butylamino)-5-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclohexanol
Synonyms:	UNC-2025; UNC2025; UNC 2025.
SMILES:	[C@@H](O)1CC[C@H](N2C3C(C(C4=CC=C(CN5CCN(C)CC5)C=C4)=C2)=CN=C(NCCCC)N=3)CC1
Formula:	C₂₈H₄₀N₆O
M.Wt:	476.66
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:

UNC2025 is a potent and orally bioavailable Mer/Flt3 dual inhibitor with IC50 of 0.8/0.74 nM for Mer/Flt3.UNC2025 was capable of inhibiting Mer phosphorylation in vivo, following oral dosing as demonstrated by pharmaco-dynamic (PD) studies examining phospho-Mer in leukemic blasts from mouse bone marrow. Kinome pro ling versus more than 300 kinases in vitro and cellular selectivity assessments demonstrate that 11 has similar subnanomolar activity against Flt3, an additional important target in acute myelogenous leukemia (AML), with pharmacologically useful selectivity versus other kinases examined.

MSDS

COA

LOT NO.	DOWNLOAD

2018-0101
2018-0101

Cat. No.	Product name	Field of application
DC11689	RU-301	RU-301 (RU301) is a small molecule pan-TAM inhibitor that targets the TAM Ig1-Gas6 interface, blocks Gas6-dependent TAM activation.
DC10127	UNC569	UNC569 is a novel small-molecule MER inhibitor with efficacy against acute lymphoblastic leukemia in vitro and in vivo.
DC7931	UNC2025	UNC2025 is a potent and orally bioavailable Mer/Flt3 dual inhibitor with IC50 of 0.8/0.74 nM for Mer/Flt3.
DC9289	UNC-2025 HCl	UNC-2025 is a potent and orally bioavailable dual MER/FLT3 inhibitor with IC50 of 0.74 nM and 0.8 nM, respectively, about 20-fold selectivity over Axl and Tyro3.
DC8223	TP-0903	TP-0903 is a a high-affinity Axl inhibitor with IC50 of 27 nM.
DC8535	SGI-7079	SGI-7079 is a novel Axl inhibitor.
DC10071	S49076	S49076 is a novel, potent inhibitor of MET, AXL/MER, and FGFR1/2/3 with IC50 values below 20 nM.
DC11265	S49076 (hydrochloride)	S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab.